Pfizer RSV vaccine may protect high-risk adults ages 18-59
Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are…
GSK RSV vaccine shows potential to protect adults 50 to 59
A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial…
CDC recommends Pfizer maternal shot for infants
A doctor vaccinates an infant against respiratory syncytial virus (RSV) in a treatment room of her paediatric practice. Swen Pförtner | Picture Alliance | Getty Images The Centers for Disease…
FDA approves Pfizer maternal vaccine for infants
CFOTO | Future Publishing | Getty Images The Food and Drug Administration on Monday approved a vaccine from Pfizer that protects infants from respiratory syncytial virus, the leading cause of…
GSK sues Pfizer claiming RSV vaccine patent infringement
Jun Li | Istock | Getty Images GlaxoSmithKline on Wednesday sued Pfizer in U.S. court, alleging patent infringement over Britain-based GSK’s respiratory syncytial virus vaccine. GSK claims New York-based Pfizer’s…
RSV vaccine uptake will start slower than shingles shot: GSK CEO
Budrul Chukrut | Lightrocket | Getty Images GlaxoSmithKline CEO Emma Walmsley on Wednesday said she expects uptake for the company’s new RSV vaccine to start off slower than it did…
CDC recommends Pfizer, GSK shots for older adults
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images The Centers for Disease Control and Prevention on Thursday recommended that adults ages 60 and above receive a single dose…
GSK says its RSV vaccine for older adults gives long-term protection
Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images GlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory syncytial virus,…
Pfizer adult RSV vaccine efficacy declines slightly after 18 months
Pfizer’s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The…
Pfizer, GSK RSV shots may prevent thousands of hospitalizations
Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands…